Catheter Precision, Inc. acquires Cardionomic, Inc. for USD 1,500,000 (2025)

Deal facts

Buyer: Catheter Precision, Inc.
Target: Cardionomic, Inc.
Deal value: USD 1,500,000
Announced: 8 May 2025
Status: Completed
Sector: Healthcare
Country: United States
Consideration: shares, loan-note

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

5 May 2025CompletedClosed
Catheter Precision, Inc. completes acquisition of Cardionomic, Inc.
Item 1.01. Entry into a Material Definitive Agreement. Acquisition of Assets As previously disclosed, in February 2025, Catheter Precision, Inc. (the “Company”) formed its subsidiary Cardionomix, Inc., a Nevada Corporation (“Cardionomix”), in order to pursue the acquisition of certain assets of Cardionomic, Inc., a Delaware corporation, which has ceased operations. We issued 82% of the common stoc
Source

OpinionExit Mode editorial

The completed acquisition of Cardionomic, Inc. by Catheter Precision, Inc. on 8 May 2025 offers a clear case study in how strategic buyers structure deals when cash is tight. The total consideration of 1.5 million USD is modest, yet the mechanics reveal a sophisticated approach to risk allocation. By mixing shares with a loan note, the buyer avoids a large upfront cash outlay while still offering the target founders a path to future value. This structure is common in the US healthcare sector where regulatory hurdles and clinical validation timelines can stretch out returns.

For the SME founder reading this, the use of a loan note alongside equity is a critical signal. It means the buyer is confident enough to commit capital but prudent enough to defer part of the payment until certain milestones are met or cash flow allows. This is not a clean exit where you walk away with a full cheque. It is a partnership where your continued involvement or the success of the integrated entity directly impacts the final payout. The loan note creates a specific creditor relationship that sits behind the equity in the capital structure, adding a layer of complexity to your financial position post-closing.

Regulatory clearance in the healthcare space often dictates deal speed and structure. While this transaction has completed, the reliance on non-cash instruments suggests the parties anticipated potential friction or simply wished to preserve liquidity for operational integration. In the UK or EU, similar deals might trigger competition reviews or require FCA prospectus rules if public shares were issued, but here the private nature of the entities allowed for a swift, flexible arrangement. The strategic nature of the deal implies that Catheter Precision sees a specific technology or customer base in Cardionomic that justifies the share issuance and the debt instrument.

You should review your own exit strategy this week to identify which parts of your valuation are currently tied to future performance rather than immediate cash. If you are in talks with a buyer, ask specifically how a loan note or earn-out would be secured and what triggers the release of those funds. Do not accept a deal structure that leaves your final payout entirely at the discretion of the buyer's future cash flow without clear contractual safeguards.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2025 deals More strategic acquisition deals More from Catheter Precision, Inc.All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

7 May 2026CompletedHealthcare

Shuttle Pharmaceuticals Holdings, Inc. to acquire United Dogecoin Inc.

Shuttle Pharmaceuticals Holdings, Inc. and United Dogecoin Inc. entered the Exit Mode archive.

Buyer: Shuttle Pharmaceuticals Holdings, Inc.
Target: United Dogecoin Inc.
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

29 April 2026CompletedHealthcare

MedPal AI plc to acquire Remedi Solutions Limited

MedPal AI plc and Remedi Solutions Limited entered the Exit Mode archive.

Buyer: MedPal AI plc
Target: Remedi Solutions Limited
Deal value: GBP 310,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United Kingdom deals

27 April 2026CompletedHealthcare

BIOMARIN PHARMACEUTICAL INC to acquire Amicus

BIOMARIN PHARMACEUTICAL INC and Amicus entered the Exit Mode archive.

Buyer: BIOMARIN PHARMACEUTICAL INC
Target: Amicus
Deal value: Not disclosed
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

22 April 2026CompletedHealthcare

Telomir Pharmaceuticals, Inc. to acquire TELI Pharmaceuticals, Inc.

Telomir Pharmaceuticals, Inc. and TELI Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Telomir Pharmaceuticals, Inc.
Target: TELI Pharmaceuticals, Inc.
Deal value: USD 34,389,710
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals United States deals

15 April 2026CompletedHealthcare

GSK plc to acquire 35Pharma Inc.

GSK plc has agreed to acquire 35Pharma Inc., a Canadian biopharmaceutical company, for an equity value of USD 950 million. The transaction was structured as a strategic…

Buyer: GSK plc
Target: 35Pharma Inc.
Deal value: USD 950,000,000
Deal type: strategic acquisition

Read deal Healthcare deals strategic acquisition deals Canada deals

Buyer history